Modality
Multispecific
MOA
AHRant
Target
PI3Kα
Pathway
Proteasome
PAHETAtopic Derm
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
Mar 2022
→ Sep 2030
Phase 1Current
NCT04089811
1,864 pts·Atopic Derm
2022-03→2030-09·Completed
1,864 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-224.5y awayInterim· Atopic Derm
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Complet…
Catalysts
Interim
2030-09-22 · 4.5y away
Atopic Derm
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04089811 | Phase 1 | Atopic Derm | Completed | 1864 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |